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1. Introduction 
Breast cancer is the most common cancer diagnosis among women worldwide (Jemal et al., 
2011). Significant numbers of women present with advanced metastatic breast cancer 
despite major improvements in population screening and health awareness (Breast Cancer 
Facts & Figures 2009-2010, 2009; Autier et al., 2011). Metastatic spread leads to the poor 
prognosis and incurring low survival rates of patients presenting with advanced stage 
breast cancer or tumor recurrence. Therefore, effective therapies targeting metastatic spread 
should be designed to prevent the devastating consequences of breast cancer progression. In 
this regard, novel pro-metastatic molecules must be identified and their functional roles in 
the progression of the disease need to be addressed.  
Cell–cell and cell–matrix adhesions have a profound role in the hematogenous phase of 
cancer metastasis. Tumor-associated glycans participate in these cell–cell and cell–matrix 
adhesions and their expression is associated with the metastatic potential of tumor cells and 
the prognosis of cancer patients (Hakomori, 1996; Couldrey and Green, 2000; Gorelik et al., 
2001; Kawaguchi, 2005; Korourian et al., 2008). 
We have been studying the role carbohydrates play in breast cancer metastasis (Monzavi-
Karbassi et al., 2005; Carcel-Trullols et al., 2006; Monzavi-Karbassi et al., 2007). A large body 
of evidence indicates that P-selectin expressed on endothelial cells and platelets plays a 
crucial role during hematogenous metastasis (Borsig et al., 2001; Kohler et al., 2010). In a 
murine model of breast cancer we observed that the expression of carbohydrates that react 
with the P-selectin receptor plays a major role in metastasis (Monzavi-Karbassi et al., 2005). 
This evidence indicates that P-selectin-mediated interaction of breast cancer cells with 
platelets is a relevant cellular adhesion mechanism that participates in establishing distant 
metastases. A novel finding in our work is the observation that chondroitin sulfate 
glycosaminoglycans (CS-GAGs) can serve as P-selectin ligands on breast cancer cells. This 
observation links CS-GAGs to P-selectin binding in defining the metastatic phenotype 
dependent on the interaction of cancer cells with platelets (Monzavi-Karbassi et al., 2007). 
Therefore, CS-GAGs can be targeted for development of novel anti-metastatic therapies.  
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Large variation exists in CS-GAG sequences and in proteoglycans (PGs) presenting them. 
The prevalence of a presenting core protein may predict the functional outcomes of P-
selectin-mediated adhesion of tumor cells. To use these molecules as targets for diagnostic 
or therapeutic purposes, a thorough understanding of their presentation and expression is 
necessary. This chapter reviews the biological roles of chondroitin sulfates (CS) in tumor 
development and metastasis and the role of different types of CS and the core protein 
carrying these polysaccharides. 
2. Chondroitin sulfate biosynthesis and presentation 
A relative variation in the composition of CS/DS has been reported in neoplastic tissues 
(Chiarugi and Dietrich, 1979; Bumol et al., 1982; Reisfeld and Cheresh, 1987; Olsen et al., 
1988; Alini and Losa, 1991; Vijayagopal et al., 1998; Vynios et al., 2008). 
 
 
Fig. 1. A) Proteoglycans consist of a core protein and covalently attached GAG chains. B) 
Biosynthesis of chondroitin and heparan sulfate building blocks initiates by the formation of 
a linkage tetrasaccharide attached to serine residue on the core protein. GlcA: Glucuronic 
acid; GlcNAc: N-acetyl-D-glucosamine; GalNAc: N-acetyl-D-galactosamine; Gal: Galactose; 
Xyl: xylose. 
Chondroitin sulfate (CS)/ dermatan sulfate (DS) polysaccharides are widely distributed in 
extracellular matrices and at cell surfaces as PGs, in which glycosaminoglycan (GAG) chains 
are covalently attached to a variety of core proteins (Figure 1A) (Esko et al., 1999). 
Chondroitin or heparan backbone is synthesized on the common GAG-protein linkage 
region tetrasaccharide (GlcUA-Galactose-Galactose-Xlylose) (Figure 1B), which is attached 
to specific serine residues in the respective core protein (Silbert and Sugumaran, 2002; 
Sugahara et al., 2003). 
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The Chondroitin chain backbone consists of repetitive disaccharide units containing D-
glucuronic acid (GlcUA) and N-acetyl-D-galactosamine (GalNAc) residues. They further 
differentiate into variable chains with distinct structures and functions after various 
modifications. Sulfation and epimerization will further generate CS/DS isomers (Table 1). 
DS or CS-B is a stereoisomeric variant of CS with varying proportions of L-iduronic acid 
(IdoUA) in place of GlcUA, which forms by epimerization of GlcUA to IdoUA (Table 1).  
 
Chondroitin 
type 
Disaccharide 
repeat 
Modifying enzymes
Sulfotransferase Epimerase 
A [GlcUA1-
3GalNAc(4S)] 
Carbohydrate (chondroitin-4) 
sulfotransferase 11, 12 and 13 (CHST11, 
CHST12 and CHST13)
- 
B [IdoUA(2s)┙1-
3GalNAc(4S)] 
Uronyl-2-O-sulfotransferase (UST) and
CHST11, CHST12 and Carbohydrate (N-
acetylgalactosamine 4-O) Sulfotransferase 
14 (CHST14)
Dermatan-
sulfate  
5-epimerase 
C [GlcUA1-
3GalNAc(6S)] 
Carbohydrate (chondroitin 6) 
sulfotransferase 3 (CHST3 ) and 
Carbohydrate (N-acetylglucosamine 6-O) 
sulfotransferase 7 (CHST7)
- 
D [GlcUA(2S)1-
3GalNAc(6S)]
UST, CHST3 and CHST7 - 
E [GlcUA1-
3GalNAc(4S,6S)] 
CHST11, CHST12, CHST13 and CHST15 
(N-acetylgalactosamine 4-sulfate 6-O-
sulfotransferase)
- 
iE [IdoUA┙1-
3GalNAc(4S,6S)] 
CHST11, CHST12, CHST14 and CHST15 Dermatan-
sulfate  
5-epimerase 
Table 1. Chondroitin sulfate types 
The monosulfated disaccharide A-unit [GlcUA-GalNAc(4S)] and C-unit [GlcUA-
GalNAc(6S)] are common and major components of mammalian CS chains. Disulfated 
disaccharide D-unit [GlcUA(2S)-GalNAc(6S)] and E-unit [GlcUA-GalNAc(4S,6S)] also exist 
that are based on further sulfation of monosulfated C and A units, respectively.  
CS/DS chains that often found as CS/DS hybrid structures have the potential to display an 
enormous structural diversity by embedding multiple overlapping sequences constructed 
with distinct disaccharide blocks modified by different patterns of sulfation (Kusche-
Gullberg and Kjellen, 2003; Sugahara et al., 2003). Given the complexity of these structures, 
the expression of modifying enzymes may correlate better with an aggressive tumor 
phenotype. Therefore, linking the expression of these enzymes with a functional role of cell 
surface CS glycans is highly significant  
2.1 Biological functions of CS/DS chains 
CS/DS chains specifically interact with heparin binding proteins. The interaction of DS 
chains with fibroblast growth factor (FGF) activates FGF-2 to signal cell proliferation (Penc 
et al., 1998). DS also acts as a cofactor for FGF-7 (Trowbridge et al., 2002). In addition, DS has 
been shown to bind and activate hepatocyte growth factor/scatter factor (HGF/SF), a 
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paracrine growth factor whose receptor, c-met (previously characterized as a proto-
oncogene), is also a transmembrane tyrosine kinase.  
The CS/DS chains of the PG versican, which is expressed in many tissues including kidney, 
skin, aorta, and brain, bind the adhesion molecules L- and P-selectin (Kawashima et al., 
2002), molecules that have been implicated in leukocyte trafficking, inflammatory disease, 
and tumor dissemination. Interestingly, these interactions are specifically inhibited by CS or 
DS containing the ‘E’ disaccharide unit GlcUA-GalNAc (4S, 6S) or the ‘iE’ unit IdoUA-
GalNAc (4S, 6S), respectively.  
In previous studies we found that CS/DS-GAGs are expressed on the cell surface of 
murine and human breast cancer cell lines with high metastatic capacity. This suggests 
that CS/DS-GAGs can mediate P-selectin binding and P-selectin-mediated adhesion of 
cancer cells to platelets and endothelial cells (Monzavi-Karbassi et al., 2007). In inhibition 
assays performed in vitro, we showed that among the CS types only CS-B (DS), and CS-E 
can efficiently block P-selectin binding to tumor cells (Monzavi-Karbassi et al., 2007). 
Other studies have also suggested important interactions mediated by CS-A and CS-E in 
tumor progression and metastasis (Iida et al., 2007; Li et al., 2008; Basappa et al., 2009). 
Therefore, enzymes involved in sulfation (sulfotransferases) or epimerization (DS 
epimerase) of CS chains may play a fundamental role in defining the malignant 
phenotype of breast tumors.  
The expression of several sulfotransferases including CHST11 and CHST15 appears to be 
greater in human breast carcinoma compared to normal breast tissue (Potapenko et al., 
2010). An increase in CHST11 expression is observed in malignant plasma cells from 
myeloma patients compared to normal bone-marrow plasma cells (Bret et al., 2009). In 
searches for genes involved in the transition of DCIS to IDC, Schuetz et al. (Schuetz et al., 
2006) found a significant increase in DS epimerase (Maccarana et al., 2006). 
Collectively, the evidence implicates CS/DS GAGs in a wide array of molecular and cellular 
interactions resulting in tumorigenesis and metastasis. 
3. Potential cell membrane CS/DS-carrying PGs of breast carcinoma 
Malignant neoplasms exhibit changes in production of PGs (Bumol and Reisfeld, 1982; 
Iozzo, 1985; Iozzo, 1988; Stylianou et al., 2008). The variation, abundance and function of 
CS/DS-GAGs are also affected by the expression of the PG core protein presenting them. 
Therefore, it is imperative to study these polysaccharides in the context of their carrying PG. 
PG are involved in signaling and tumorigenicity and their attached GAG contributes to their 
functions. There is a growing list of PGs that have been implicated as possessing CS/DS side 
chains (Esko et al., 1999; Taylor and Gallo, 2006). PGs that may be modified by CS/DS 
chains include aggrecan, neurocan, brevican, bamacan, a CD44 isoform, chondroitin sulfate 
proteoglycan 4 (CSPG4), syndecans, betaglycan, serglycin, versican, decorin, biglycan, and 
endocan, most of which are extracellular matrix PGs. Our focus is on the cell membrane PGs 
that are able to bind to P-selectin (Monzavi-Karbassi et al., 2007). CD44 variants (CD44v), 
CSPG4, syndecan-1 (SDC-1) and syndecan-4 (SDC-4) are among the cell surface candidates 
(Faassen et al., 1992; Jackson et al., 1995; Barbareschi et al., 2003; Burbach et al., 2003; Baba et 
al., 2006; Gotte et al., 2007; Wang et al., 2010). Recently, It has been demonstrated that 
substantial fraction of neuropilin-1 (NRP-1), a membrane glycoprotein, is a PG modified 
with either HS or CS-GAG chains (Shintani et al., 2006). 
www.intechopen.com
On the Role of Cell Surface Chondroitin Sulfates and 
Their Core Proteins in Breast Cancer Metastasis 
 
439 
Many articles are now devoted to CD44 in cancer stem cells and its role in cancer 
progression and metastasis (Lesley et al., 1997; Naor et al., 1997; Lesley and Hyman, 1998; 
Kalish et al., 1999; Toole, 2009). Here we focus on SDC-1, SDC-4, CSPG4 and NRP-1 as 
potential CS-carrying PGs on the surface of breast tumor cells.  
3.1 Role of CS-carrying PGs in tumor progression and metastasis 
Alteration in the production and structure of GAG chains and the functional consequences 
of such alterations is dependent on the PG carrying the GAG chain. PGs isolated from 
carcinomas contained 32.2% more CS, 18% less DS, and 30% less HS than PGs of normal 
breast tissue (Vijayagopal et al., 1998). Chondroitin sulfate proteoglycans (CSPGs) were 
expressed significantly more often in metastases than in primary tumors of uveal melanoma 
(Kiewe et al., 2006). We have recently found that CSPGs on breast cancer cells also bind to P-
selectin receptors, and interruption of this interaction leads to significant reduction in 
hematogenous metastasis (Monzavi-Karbassi et al., 2007).  
Selectin-mediated binding of tumor cells to platelets, leukocytes, and vascular endothelium 
may regulate their hematogenous spread in the microvasculature (Krause and Turner, 1999). 
Among selectin molecules, evidence strongly supports P-selectin involvement in tumor 
metastasis (Kim et al., 1998; Stevenson et al., 2005). Our data suggest that inhibition of P-
selectin interaction with CS-GAGs significantly attenuates hematogenous lung metastasis 
(Monzavi-Karbassi et al., 2007). We have demonstrated that P-selectin binding to the surface 
of the aggressive breast cancer cell line MDA-MB-231 and MDA-MET is also CS-dependent, 
suggesting a role for CSPGs in metastatic behavior of human cancer cells. Because of the role 
of some of these PGs in signaling and tumor phenotype, we speculate that P-selectin 
interaction with a particular PG may lead to an exclusive tumor cell activation, and 
consequently survival in circulation. Here, we review the role of the surface PGs able to 
present CS-GAGs in malignancy.  
3.1.1 CSPG4 
CSPG4 is a human homolog of Rat neuroglycan 2 (NG2), which is also known as High 
Molecular Weight Melanoma Associated Antigen and Melanoma Chondroitin Sulfate 
Proteoglycan (Stallcup, 1981; Bumol and Reisfeld, 1982; Pluschke et al., 1996) and 
exclusively carries CS chains (Bumol and Reisfeld, 1982; Nishiyama et al., 1991). This tumor-
associated cell surface PG potentiates cell motility, promotes invasiveness and the metastatic 
potential of tumor cells in melanoma (Burg et al., 1998; Campoli et al., 2004; Iida et al., 2007; 
Wang et al., 2010), and modulates responses to growth factors (Grako and Stallcup, 1995; 
Yang et al., 2009), processes that are critical for the proliferation and migration of tumor 
cells. It is suggested that CSPG4 facilitates the invasion of aggressive primary tumors within 
the dermis by enhancing the local concentration and/or activation of specific matrix 
metalloproteinases (MMPs) at sites of contact between melanoma cells and the underlying 
ECM (Iida et al., 2001). The authors demonstrated that CSPG4 on WM1341D cells, interacts 
with membrane-type matrix metalloproteinase (MT3-MMP), facilitating invasion, and that 
the interaction is CS-dependent. Inhibiting CS presentation by treating cells with p-
nitrophenyl beta-D-xylopyranoside (beta-D-xyloside or DX), a compound that uncouples 
the CS chain from the PG, led to a decrease in melanoma cell invasion into type I collagen 
(Faassen et al., 1992). CSPG4 is highly expressed on aggressive breast cancer cell lines 
(Figure 2) and is considered as a major CS-carrying PG.  
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Fig. 2. Expression of NRP-1, SDC-4 and CSPG4 in breast cancer cells. Cells were grown in 
standard medium, harvested and then stained with monoclonal antibodies against the 
indicated targets. Stained cells were then analyzed by flow cytometry.  
3.1.2 NRP-1 
NRP-1 is a 120-130 kDa transmembrane glycoprotein, initially characterized as a neuronal 
receptor for specific secreted members of the semaphorin family involved in exon 
repulsation (Kolodkin et al., 1997). A substantial fraction of NRP-1 is a PG with a GAG chain 
attached (Shintani et al., 2006). In addition to being a receptor for a number of class 3 
semaphorins, NRP-1 also serves as a receptor for some members of vascular endothelial 
growth factor (VEGF), and placental growth factor (PlGF) (Migdal et al., 1998; Soker et al., 
1998; Makinen et al., 1999; Wise et al., 1999; Klagsbrun et al., 2002). 
Considerable data support a functional role for NRP-1 in regulating VEGF activities in 
endothelium. It has been shown that semaphorin-3A competes with VEGF165 binding to NRP-1 
and inhibits angiogenesis in vitro (Miao et al., 1999). NRP-1 knock-out mice, in addition to 
neural defects, exhibit transposition of large vessels, disorganized and insufficient capillary 
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formation, and defects in heart development (Kawasaki et al., 1999). In contrast, over-
expression of NRP-1 leads to over-stimulation of blood vessel formation (Kitsukawa et al., 
1995). Studies have shown that NRP-1interacts with a subset of heparin binding proteins like 
FGF-1, FGF-2, FGF-4, FGF-7, FGF receptor-1, and HGF/SF (West et al., 2005). Investigation of 
the role of NRP-1 in human glioma progression, Hu et al. (Hu et al., 2007) have shown that 
NRP-1 expression correlates with tumor progression in clinical setting, and that NRP-1 
expression promotes tumor growth and survival through an autocrine HGF/SF/c-met 
signaling pathway. We observed an overexpression of NRP-1 in aggressive human breast 
cancer cell line MDA-MB-231 compare to MCF-7 cells (Figure 2). This PG is also considered as 
a potential CS-carrying PG that can present CS-GAGs to P-selectin.  
3.1.3 SDC-1 and SDC-4 
SDC-1 is mainly expressed by epithelia and plasma cells. Although there are inconsistent 
reports (Barbareschi et al., 2003; Tsanou et al., 2004), the expression of SDC-1 is generally 
down-regulated in malignant tumors, and lower levels of expression have been associated 
with high metastatic/aggressive potential in many tumors (Nackaerts et al., 1997; Kumar-
Singh et al., 1998; Mikami et al., 2001; Numa et al., 2002). SDC-1 has also been shown to act 
as a tumor suppressor molecule by inhibiting cell growth and inducing apoptosis (Mali et 
al., 1994; Dhodapkar et al., 1998). Therefore, during tumor development the decrease of 
SDC-1 expression may be an important step from tumorigenesis to a metastatic phenotype. 
However, there are conflicting data on the role of SDC-1; both its loss and over-expression in 
carcinoma cells have been associated with malignant progression (Baba et al., 2006).  
SDC-4 is more ubiquitously expressed by most cell types, and little is known about its role 
in malignancy. Among the four members of the syndecan family, SDC-4 is the only one 
involved in the formation of fibronectin-induced focal adhesions, in cooperation with ┚1-
integrin receptors (Woods and Couchman, 1994; Woods et al., 2000). SDC-4 has been 
implicated in cytoskeletal organization and regulation of cell adhesiveness. The migratory 
capacity of lymphocytes and dendritic cells has been reported to be mediated by SDC-4 
(Kaneider et al., 2002; Greene et al., 2003; Feistritzer et al., 2004; Averbeck et al., 2007). Our 
data suggest a role for relative expression of SDC-1 and SDC-4, low SDC-1 and high SDC-4 
expression, in metastatic breast cancer cells (Figure 3).  
 
 
Fig. 3. Relative expression of SDC-1 and SDC-4 in human breast cancer cells using 
quantitative real-time PCR. Means of three independent experiments (±SD) are shown.  
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Therefore, relative expression of certain PGs or modification in their GAG chains may affect 
tumor aggressive phenotype through promoting survival, growth, and the metastatic 
capability of tumor cells. P-selectin can bind to CS-GAGs of these PGs and binding to each 
PG can have different functional consequences. These molecules has been linked to motility, 
invasion, angiogenesis, and cancer stem cell properties. Therefore, depending on the setting 
and expression of other molecules, P-selectin interaction may lead to various tumor 
promoting outcomes.  
In studying the role of P-selectin in tumor growth and metastasis in a P-selectin-deficient 
Rag2-/- background, it was demonstrated that growth of subcutaneously challenged tumor 
cells were reduced significantly in the absence of P-selectin (Kim et al., 1998). This 
significantly slower growth rate in P-selectin deficient mice was unexpected because P-
selectin is assumed to play a role in leukocytic infiltrates within tumors, which are generally 
inversely associated with tumor growth (Kreider et al., 1984). These findings, consistent 
with our hypothesis, demonstrate that the presence of P-selectin ligands on tumor cells and 
P-selectin-mediated interactions with stroma leads to tumorigenesis and tumor growth 
promotion.  
4. Diagnostic and therapeutic values 
Overexpression of particular CS chains can be used to develop diagnostic tests predicting 
tumor behavior or for prognostic purposes. In this regard, further attempts should be made 
to link the expression of a combination of genes that define GAG remodeling to the 
initiation and outcome of the disease in clinical setting.  
Expression of CS can also be used for drug delivery purposes. Polyethylene glycol coated 
liposomes, containing a cationic lipid with CS specificity were used to deliver cisplatin to 
metastatic tumor cells (Lee et al., 2002). The cisplatin loaded CS-reactive liposomes 
suppressed metastatic spread of the murine osteosarcoma cells to the liver.  
We have shown CS interactions with P-selectin and the significance of P-selectin binding in 
metastasis of a murine mammary cell line (Monzavi-Karbassi et al., 2007). Our findings 
support the concept that CS chains promote survival in the circulation, and tumor cell 
extravasation via P-selectin-mediated binding to platelets and endothelial cells. Using 
heparin to block P-selectin binding to tumor cells as anti-metastatic therapy has been the 
subject of many studies (Borsig et al., 2001; Stevenson et al., 2005). However, blocking P-
selectin action through the inhibition of binding to its many ligands may affect cellular 
immunity that could be a tumor friendly side effect of a potential treatment. To avoid 
unfavorable impact of such a treatment on lymphocyte trafficking and infiltration, targeting 
relevant tumor-specific P-selectin ligands should be prioritized as an alternative long-term 
therapeutic strategy for aggressive breast cancer.  
To develop therapeutics targeting CS entity we envision three major strategies. 1) Targeting 
particular CS types through blocking the expression of particular CS structures or the usage 
of small molecules, is supposed to attenuate metastasis efficiency. In this category, blocking 
the expression of a key sulfotransferase with siRNA may be considered a potential 
therapeutic approach at this point. Development of small molecules with fine specificity can 
also be proposed for blocking particular isomers of CS with reactive molecules. 2) Specific 
targeting of a prominent CS-carrying PG with definite impact on tumor progression and 
metastasis. CSPG4 is considered a prominent CSPG with a tumor promoting role. MAb 
targeting CSPG4 have been developed in melanoma and testing them for treatment of 
www.intechopen.com
On the Role of Cell Surface Chondroitin Sulfates and 
Their Core Proteins in Breast Cancer Metastasis 
 
443 
patients with aggressive breast cancer falls in line with our data (Wang et al., 2010a; Wang et 
al., 2010b). However, targeting a core protein may bring in specificity issues as these PGs are 
also expressed in stroma. Additionally, tumor cells can escape treatment by immune editing 
and replacing a PG with another one. 3) Targeting a combination of sugar and PG that can 
be accomplished by simultaneous targeting of the core protein and the polysaccharide, or by 
developing reagents like mAb specific for the whole entity (polysaccharide and the core 
protein).  
5. Conclusion 
Breast cancer cell surface CS-GAGs and their interaction with P-selectin should be 
considered as viable targets for the development of novel diagnostic or therapeutic 
strategies. Our studies suggest that CS-GAGs, their biosynthetic pathway, or the core 
protein carrying them, can be potential targets in dealing with aggressive breast tumors. 
However, in order to efficiently block tumor cell dissemination by interrupting P-
selectin/CS interaction, targeting any single PG does not seem to be enough, as other PGs 
can probably compensate and support metastatic processes. In this regard, global targeting 
of specific CS isomers, or combined targeting of the glycan and the PG, may be effective 
approaches.  
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